A Basic ApoE-Based Peptide Mediator to Deliver Proteins across the Blood-Brain Barrier: Long-Term Efficacy, Toxicity, and Mechanism

Yu Meng, Jennifer A. Wiseman, Yuliya Nemtsova, Dirk Moore, Jenieve Guevarra, Kenneth Reuhl, William A. Banks, Richard Daneman, David E. Sleat, Peter Lobel

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

We have investigated delivery of protein therapeutics from the bloodstream into the brain using a mouse model of late-infantile neuronal ceroid lipofuscinosis (LINCL), a lysosomal disease due to deficiencies in tripeptidyl peptidase 1 (TPP1). Supraphysiological levels of TPP1 are delivered to the mouse brain by acute intravenous injection when co-administered with K16ApoE, a peptide that in trans mediates passage across the blood-brain barrier (BBB). Chronic treatment of LINCL mice with TPP1 and K16ApoE extended the lifespan from 126 to >294 days, diminished pathology, and slowed locomotor dysfunction. K16ApoE enhanced uptake of a fixable biotin tracer by brain endothelial cells in a dose-dependent manner, suggesting that its mechanism involves stimulation of endocytosis. Pharmacokinetic experiments indicated that K16ApoE functions without disrupting the BBB, with minimal effects on overall clearance or uptake by the liver and kidney. K16ApoE has a narrow therapeutic index, with toxicity manifested as lethargy and/or death in mice. To address this, we evaluated variant peptides but found that efficacy and toxicity are associated, suggesting that desired and adverse effects are mechanistically related. Toxicity currently precludes direct clinical application of peptide-mediated delivery in its present form but it remains a useful approach to proof-of-principle studies for biologic therapies to the brain in animal models.

Original languageEnglish (US)
Pages (from-to)1531-1543
Number of pages13
JournalMolecular Therapy
Volume25
Issue number7
DOIs
StatePublished - Jul 5 2017

Fingerprint

Apolipoproteins E
Blood-Brain Barrier
Neuronal Ceroid-Lipofuscinoses
Peptides
Brain
Proteins
Lethargy
Biological Therapy
Biotin
Endocytosis
Intravenous Injections
Therapeutics
Endothelial Cells
Animal Models
Pharmacokinetics
Pathology
Kidney
Liver
tripeptidyl-peptidase 1

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery

Keywords

  • blood brain barrier
  • enzyme replacement therapy
  • intravenous
  • tripeptidyl peptidase 1

Cite this

Meng, Yu ; Wiseman, Jennifer A. ; Nemtsova, Yuliya ; Moore, Dirk ; Guevarra, Jenieve ; Reuhl, Kenneth ; Banks, William A. ; Daneman, Richard ; Sleat, David E. ; Lobel, Peter. / A Basic ApoE-Based Peptide Mediator to Deliver Proteins across the Blood-Brain Barrier : Long-Term Efficacy, Toxicity, and Mechanism. In: Molecular Therapy. 2017 ; Vol. 25, No. 7. pp. 1531-1543.
@article{a6ca17647adb4956a595b4d666ba785d,
title = "A Basic ApoE-Based Peptide Mediator to Deliver Proteins across the Blood-Brain Barrier: Long-Term Efficacy, Toxicity, and Mechanism",
abstract = "We have investigated delivery of protein therapeutics from the bloodstream into the brain using a mouse model of late-infantile neuronal ceroid lipofuscinosis (LINCL), a lysosomal disease due to deficiencies in tripeptidyl peptidase 1 (TPP1). Supraphysiological levels of TPP1 are delivered to the mouse brain by acute intravenous injection when co-administered with K16ApoE, a peptide that in trans mediates passage across the blood-brain barrier (BBB). Chronic treatment of LINCL mice with TPP1 and K16ApoE extended the lifespan from 126 to >294 days, diminished pathology, and slowed locomotor dysfunction. K16ApoE enhanced uptake of a fixable biotin tracer by brain endothelial cells in a dose-dependent manner, suggesting that its mechanism involves stimulation of endocytosis. Pharmacokinetic experiments indicated that K16ApoE functions without disrupting the BBB, with minimal effects on overall clearance or uptake by the liver and kidney. K16ApoE has a narrow therapeutic index, with toxicity manifested as lethargy and/or death in mice. To address this, we evaluated variant peptides but found that efficacy and toxicity are associated, suggesting that desired and adverse effects are mechanistically related. Toxicity currently precludes direct clinical application of peptide-mediated delivery in its present form but it remains a useful approach to proof-of-principle studies for biologic therapies to the brain in animal models.",
keywords = "blood brain barrier, enzyme replacement therapy, intravenous, tripeptidyl peptidase 1",
author = "Yu Meng and Wiseman, {Jennifer A.} and Yuliya Nemtsova and Dirk Moore and Jenieve Guevarra and Kenneth Reuhl and Banks, {William A.} and Richard Daneman and Sleat, {David E.} and Peter Lobel",
year = "2017",
month = "7",
day = "5",
doi = "10.1016/j.ymthe.2017.03.037",
language = "English (US)",
volume = "25",
pages = "1531--1543",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "7",

}

A Basic ApoE-Based Peptide Mediator to Deliver Proteins across the Blood-Brain Barrier : Long-Term Efficacy, Toxicity, and Mechanism. / Meng, Yu; Wiseman, Jennifer A.; Nemtsova, Yuliya; Moore, Dirk; Guevarra, Jenieve; Reuhl, Kenneth; Banks, William A.; Daneman, Richard; Sleat, David E.; Lobel, Peter.

In: Molecular Therapy, Vol. 25, No. 7, 05.07.2017, p. 1531-1543.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A Basic ApoE-Based Peptide Mediator to Deliver Proteins across the Blood-Brain Barrier

T2 - Long-Term Efficacy, Toxicity, and Mechanism

AU - Meng, Yu

AU - Wiseman, Jennifer A.

AU - Nemtsova, Yuliya

AU - Moore, Dirk

AU - Guevarra, Jenieve

AU - Reuhl, Kenneth

AU - Banks, William A.

AU - Daneman, Richard

AU - Sleat, David E.

AU - Lobel, Peter

PY - 2017/7/5

Y1 - 2017/7/5

N2 - We have investigated delivery of protein therapeutics from the bloodstream into the brain using a mouse model of late-infantile neuronal ceroid lipofuscinosis (LINCL), a lysosomal disease due to deficiencies in tripeptidyl peptidase 1 (TPP1). Supraphysiological levels of TPP1 are delivered to the mouse brain by acute intravenous injection when co-administered with K16ApoE, a peptide that in trans mediates passage across the blood-brain barrier (BBB). Chronic treatment of LINCL mice with TPP1 and K16ApoE extended the lifespan from 126 to >294 days, diminished pathology, and slowed locomotor dysfunction. K16ApoE enhanced uptake of a fixable biotin tracer by brain endothelial cells in a dose-dependent manner, suggesting that its mechanism involves stimulation of endocytosis. Pharmacokinetic experiments indicated that K16ApoE functions without disrupting the BBB, with minimal effects on overall clearance or uptake by the liver and kidney. K16ApoE has a narrow therapeutic index, with toxicity manifested as lethargy and/or death in mice. To address this, we evaluated variant peptides but found that efficacy and toxicity are associated, suggesting that desired and adverse effects are mechanistically related. Toxicity currently precludes direct clinical application of peptide-mediated delivery in its present form but it remains a useful approach to proof-of-principle studies for biologic therapies to the brain in animal models.

AB - We have investigated delivery of protein therapeutics from the bloodstream into the brain using a mouse model of late-infantile neuronal ceroid lipofuscinosis (LINCL), a lysosomal disease due to deficiencies in tripeptidyl peptidase 1 (TPP1). Supraphysiological levels of TPP1 are delivered to the mouse brain by acute intravenous injection when co-administered with K16ApoE, a peptide that in trans mediates passage across the blood-brain barrier (BBB). Chronic treatment of LINCL mice with TPP1 and K16ApoE extended the lifespan from 126 to >294 days, diminished pathology, and slowed locomotor dysfunction. K16ApoE enhanced uptake of a fixable biotin tracer by brain endothelial cells in a dose-dependent manner, suggesting that its mechanism involves stimulation of endocytosis. Pharmacokinetic experiments indicated that K16ApoE functions without disrupting the BBB, with minimal effects on overall clearance or uptake by the liver and kidney. K16ApoE has a narrow therapeutic index, with toxicity manifested as lethargy and/or death in mice. To address this, we evaluated variant peptides but found that efficacy and toxicity are associated, suggesting that desired and adverse effects are mechanistically related. Toxicity currently precludes direct clinical application of peptide-mediated delivery in its present form but it remains a useful approach to proof-of-principle studies for biologic therapies to the brain in animal models.

KW - blood brain barrier

KW - enzyme replacement therapy

KW - intravenous

KW - tripeptidyl peptidase 1

UR - http://www.scopus.com/inward/record.url?scp=85018699926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018699926&partnerID=8YFLogxK

U2 - 10.1016/j.ymthe.2017.03.037

DO - 10.1016/j.ymthe.2017.03.037

M3 - Article

C2 - 28456380

AN - SCOPUS:85018699926

VL - 25

SP - 1531

EP - 1543

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 7

ER -